Seattle Genetics Inc. announced data from an ongoing Phase I clinical trial evaluating SGN-CD33A, an antibody-drug conjugate, or ADC, in development for the treatment of acute myeloid leukemia, or AML. SGN-CD33A is a novel ADC targeted to CD33 utilizing Seattle Genetics' newest technology. CD33 is expressed on most AML cells regardless of subtype, cytogenetic abnormality or underlying mutational heterogeneity.

SGN-CD33A is the first ADC utilizing an engineered cysteine antibody (EC-mAb) and pyrrolobenzodiazepine (PBD) dimer to be advanced into the clinic.